The MK2 pathway has been less studied compared to p38, however, some data suggest that the MK2 inhibitor MK2.III increases the sensitivity of pancreatic cancer cells to gemcitabine [111], and recent data show that MK2 knockdown reduces in vivo growth of multiple myeloma in mouse models with MK2 overexpression leading to bortezomib and doxorubicin chemoresistance by reducing apoptosis [112]. The gene discussed is MAPKAPK2; the disease is familial pancreatic carcinoma.